论文部分内容阅读
目的 :通过研究临床上采用哌拉西林钠他唑巴坦钠治疗肺结核合并社区获得性肺炎的疗效,从而为临床治疗提供有效证据。方法 :随机选取我院2014年2月-2015年2月的肺结合合并社区获得性肺炎患者80例,将这80例患者随机均分为两组,即对照组和实验组,每组40人。实验组的40例患者采用哌拉西林钠/他唑巴坦钠进行治疗,对照组的40例患者采用头孢哌酮/舒巴坦钠进行治疗。通过统计学软件SPSS10.0对两组患者的临床疗效、不良反应、细菌清除率等数据进行统计分析。结论 :采用哌拉西林钠他唑巴坦钠治疗的实验组患者总有效率95%,细菌清除率92%,而采用头孢哌酮舒巴坦钠治疗的对照组患者总有效率85%,细菌清除率83.3%。无论是治疗效果还是细菌清除情况,采用哌拉西林钠他唑巴坦钠治疗的实验组均明显高于采用头孢哌酮舒巴坦钠治疗的对照组。说明对于肺结核合并社区获得性肺炎患者采用哌拉西林钠他唑巴坦钠治疗疗效更加确切。
Objective: To study the clinical efficacy of piperacillin-tazobactam sodium in the treatment of pulmonary tuberculosis complicated with community-acquired pneumonia, so as to provide effective evidence for clinical treatment. Methods: Eighty patients with lung-associated and community-acquired pneumonia were randomly selected in our hospital from February 2014 to February 2015. The 80 patients were randomly divided into two groups: control group and experimental group, with 40 patients in each group . Forty patients in the experimental group were treated with piperacillin / tazobactam sodium and 40 patients in the control group were treated with cefoperazone / sulbactam sodium. Through statistical software SPSS10.0 two groups of patients clinical efficacy, adverse reactions, bacterial clearance rate and other data for statistical analysis. Conclusion: The experimental group treated with piperacillin and tazobactam sodium had a total effective rate of 95% and a bacterial clearance rate of 92%, while the control group treated with cefoperazone and sulbactam had a total effective rate of 85% Clearance rate of 83.3%. Both the therapeutic effect and bacterial clearance, the experimental group treated with piperacillin-tazobactam sodium was significantly higher than the control group treated with cefoperazone-sulbactam sodium. This shows that the treatment of tuberculosis combined with community-acquired pneumonia with piperacillin and tazobactam sodium is more effective.